Nov 27, 2023, 03:42pm

To: Jessica Schwartzman, PhD
DEVELOPMENTAL-BEHAVIORAL PEDIATRICS - CHLA
From: Children's Hospital Los Angeles Institutional Review Board
Re: CHLA-23-00278
Reward Responsivity and Depression in Autism (RRDA) (RRDA)

NOTICE OF IRB APPROVAL

Valid from: 11/21/2023 Expires: 11/20/2024

Document(s) Reviewed:

- **iStar Application (version date 11/9/2023)**
- **RRDA CHLA Protocol (version date 11/4/2023)**
- **Consent/Permission/Assent Form (version date 11/4/2023)**

The above-named study was reviewed by the CHLA IRB at a convened meeting on **11/21/2023.** The study has been approved.

It has been determined that the research involves no greater than minimal risk.

The IRB agreed with the PI's explanation that the EyeLink 1000 Plus is non-significant risk. Additionally, the IRB determined and documented in writing its own rationale that the device is non-significant risk.

The approved consent document(s) can be found under the approved documents link in iStar. Only informed consent documents with the IRB approval watermark may be used.

It has been determined that children may be included in the research. The IRB determined and documented that the research meets the requirements of 45 CFR 46.404/21 CFR 50.51.

When enrolling a minor into this research, the permission of at least one parent/legal guardian is required.

The written assent of all of the children is necessary for participating in the research.

For the purposes of deception, this study has been granted an alteration of informed consent/assent/permission per 45 CFR 46.116(f)

CHLA Research HIPAA authorization is required for this research as subject's protected health information is being accessed, used, or disclosed for purposes of this research. Approved CHLA Research HIPAA templates are available at www.chla.org/research/hspp. Any changes to the approved template language, such as those requested by study sponsors, must be approved by the IRB prior to use. HIPAA authorization should be obtained from the adult subject (or the surrogate for adults not capable of providing authorization) or from the parent (for minor subjects). When subjects turn 18 and continue on the research, HIPAA authorization must be obtained from those subjects.

The Experimental Subject's Bill of Rights must be signed and dated at the beginning of the consent conference to enroll a subject into this research. The Experimental Subject's Bill of Rights may be found here: www.chla.org/research/hspp. The Experimental Subject's Bill of Rights should be signed by the adult subject (or the surrogate for adults not capable of providing consent) or the parent (for minor subjects).

IRB approval for this study will expire on the expiration date noted above. In order to continue the research beyond the expiration date, a Continuing Review application must be received by the HSPP office at least 8 weeks before the expiration date, and continuation of the study must be approved by the IRB. The iStar application should be closed once the research has been completed.

This is an auto-generated email. **Print this notice for your records.** Please do not respond directly to this message using the "reply" address. A response sent in this manner cannot be answered. If you have further questions about this letter, please contact the CHLA HSPP Office at (323) 361-2265 or hspp@chla.usc.edu.